← Browse by Condition
Medical Condition

renal cell carcinoma

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for renal cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — renal cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for renal cell carcinoma?
ClinicalMetric currently tracks 9 actively recruiting clinical trials for renal cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for renal cell carcinoma?
renal cell carcinoma research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a renal cell carcinoma clinical trial?
Eligibility criteria for renal cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
3
Top Sponsors
Jinling Hospital, China 1 trial
Royal Marsden NHS Foundation Trust 1 trial
Diwakar Davar 1 trial
Regina Elena Cancer Institute 1 trial
Yale University 1 trial

Recruiting Clinical Trials

NCT05917106
Recruiting
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Enrollment
450 pts
Location
China
Sponsor
Jinling Hospital, China
View Trial →
NCT06995664
Recruiting
Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management
Enrollment
24 pts
Location
United Kingdom
Sponsor
Royal Marsden NHS Foundation T...
View Trial →
NCT07223424 Phase 2
Recruiting
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Enrollment
880 pts
Location
United States
Sponsor
Diwakar Davar
View Trial →
NCT07018037
Recruiting
Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
Enrollment
20 pts
Location
Italy
Sponsor
Regina Elena Cancer Institute
View Trial →
NCT04974671 Phase 2
Recruiting
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Enrollment
30 pts
Location
United States
Sponsor
Yale University
View Trial →
NCT06444815 Phase 1
Recruiting
A Study of VET3-TGI in Patients With Solid Tumors
Enrollment
60 pts
Location
United States
Sponsor
KaliVir Immunotherapeutics
View Trial →
NCT05048212 Phase 2
Recruiting
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
Enrollment
20 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT07195682 Phase 1
Recruiting
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment
125 pts
Location
United States, Canad...
Sponsor
Bristol-Myers Squibb
View Trial →
NCT05810571
Recruiting
Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study
Enrollment
60 pts
Location
Turkey (Türkiye)
Sponsor
Kocaeli University
View Trial →

Related Conditions

kidney cancer (2) non small cell lung cancer (2) squamous cell carcinoma (2) cervical cancer (2) carcinoma (1) rcc (1) kidney neoplasms (1) renal cell carcinoma metastatic (1) melanoma (1) colo rectal cancer dmmr msi h crc (1) hepatocellular carcinoma (1) ulcerative colitis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology